For posterior non-infectious uveitis, what is a typical treatment approach?

For posterior non-infectious uveitis, what is a typical treatment approach?

• A. Topical antibiotics
• B. Local heat and rest
• C. Systemic corticosteroids
• D. Periocular or systemic corticosteroids with immunomodulatory therapy as needed

Answer: (D)

The main idea here is that controlling inflammation in the back part of the eye typically requires corticosteroids delivered where the disease is active, with additional immune-modulating therapy to maintain control and reduce steroid exposure over time. For posterior non-infectious uveitis, starting with corticosteroids is common because they rapidly suppress intraocular inflammation. Delivering them periocularly (around the eye) or systemically ensures the posterior segment receives effective drug levels, which topical forms alone cannot provide. Adding immunomodulatory therapy as needed is key when the inflammation is chronic, recurrent, or difficult to control with steroids alone. These steroid-sparing agents—such as methotrexate, azathioprine, mycophenolate, or other immunosuppressants—help maintain long-term control and allow tapering of corticosteroids, reducing the risk of systemic and ocular side effects while protecting vision. The other options fall short because they don’t adequately address posterior inflammation: topical antibiotics don’t treat noninfectious inflammatory processes; local heat and rest have no proven therapeutic effect for active uveitis; and relying on systemic steroids alone without IMT may be insufficient for chronic or refractory cases and can lead to steroid-related complications.

The main idea here is that controlling inflammation in the back part of the eye typically requires corticosteroids delivered where the disease is active, with additional immune-modulating therapy to maintain control and reduce steroid exposure over time. For posterior non-infectious uveitis, starting with corticosteroids is common because they rapidly suppress intraocular inflammation. Delivering them periocularly (around the eye) or systemically ensures the posterior segment receives effective drug levels, which topical forms alone cannot provide.

Adding immunomodulatory therapy as needed is key when the inflammation is chronic, recurrent, or difficult to control with steroids alone. These steroid-sparing agents—such as methotrexate, azathioprine, mycophenolate, or other immunosuppressants—help maintain long-term control and allow tapering of corticosteroids, reducing the risk of systemic and ocular side effects while protecting vision.

The other options fall short because they don’t adequately address posterior inflammation: topical antibiotics don’t treat noninfectious inflammatory processes; local heat and rest have no proven therapeutic effect for active uveitis; and relying on systemic steroids alone without IMT may be insufficient for chronic or refractory cases and can lead to steroid-related complications.